Medicare ACO Cost Incentives For Part B-To-D Rx Shifts Worry Stakeholders

CMS should look for ways to ensure that financial incentives for Medicare accountable care organizations do not promote inappropriate shifts in prescribing from the Part B benefit to Part D, biotech and clinician groups urge in comments filed with the agency June 6.